Leveraging Phenotypic Data in Severe Asthma Control: Are You Individualizing Your Patient's Treatment?

Release Date: July 15, 2020
Expiration Date: July 15, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in asthma treatment to provide insight on how to manage patients with severe, uncontrolled asthma. Asthma is a chronic inflammatory disease with distinct phenotypes that originates from a complex interplay between genetic and environmental factors. Exploring an individual’s asthma phenotype is becoming increasingly important to help select the optimal targeted therapy that aims at controlling symptoms and reducing the risk of future exacerbations.

This educational activity is an archive of a live virtual symposium held on June 24, 2020.

Acknowledgment of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline plc.

Target Audience

This educational program is directed toward all pulmonologists, allergists, and primary care physicians.

Nurses, nurse practitioners, physician assistants, and other healthcare providers who treat patients with asthma may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Discuss the role of eosinophils in the spectrum of eosinophilic asthma phenotypes
• Evaluate the efficacy and safety of therapies for patients with eosinophilic asthma
• Develop strategies for shared decision making and asthma action plans with patients affected by eosinophilic asthma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Paul P. Doghramji, MD, FAAFP
Senior Attending Physician, Collegeville Family Practice
Medical Director, Health Services, Ursinus College
Cofounder, Brookside Family Practice and Pediatrics
Pottstown, PA

Disclosures: Paul P. Doghramji, MD, FAAFP has no relevant financial relationships with commercial interest to disclose.

Sandhya Khurana, MD
Professor, Pulmonary and Critical Care Medicine
Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester School of Medicine and Dentistry
Rochester, NY

Disclosures: Grant Research Support: GlaxoSmithKline, Sanofi.

Diego Maselli, MD, FCCP
Associate Professor of Medicine
Division of Pulmonary Diseases and Critical Care
University of Texas Health Science Center at San Antonio
Medical Director, Respiratory Care
Medical Director, Severe Asthma Program
University of Texas Health
San Antonio, TX

Disclosures: Grant Research Support: AstraZeneca; Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi; Speakers Bureau: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi, Sunovion.

Mike Wechsler, MD, MMSc
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
Director, The Cohen Family Asthma Institute
National Jewish Health
Denver, CO

Disclosures: Grant Research Support: AstraZeneca, Regeneron Sanofi, Teva; Consultant: AstraZeneca, Equillium, Genentech, Genzyme, GlaxoSmithKline, Novartis, Regeneron, resTORbio , Sanofi.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.